chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia, Pyrexia
Clinical narrative: Speechless; Brain fog; Anxiety attack; Feel awful.; Fever; Muscle ache; Chills; Tingling in head and lowered back; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old, non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration on 09Apr2021 at 13:45 (at an age of 40-years-old) as single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within 4 weeks prior to COVID vaccine. The patient did not receive any concomitant medications.  On 16Apr2021, the patient had tingling in head and lowered back, chills, fever, speechless, brain fog, anxiety attack, muscle ache symptoms were on going for a week, felt awful. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events of tingling in head and lowered back, chills, fever, speechless, brain fog, anxiety attack, muscle ache and felt awful were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metallic taste in mouth; This is a spontaneous report from a contactable consumer. A male patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 23Apr2021 (age at vaccination unknown) as a single dose for COVID-19 immunisation. It was unknown if the patient had any other medical history and known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination were not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (age at vaccination unknown) as a single dose for COVID-19 immunisation. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. It was not known if the patient received any other vaccines within four weeks prior to the vaccination. On 23Apr2021, the patient experienced metallic taste in mouth. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event metallic taste in mouth was resolved on 23Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Axillary pain, Burning sensation, Fatigue, Hypokinesia
Clinical narrative: Tiredness; Low back stiffness; pain; Severe shoulder pain; burning; cannot lift arm; Painful armpit; This is a spontaneous report from a contactable Consumer or other non-HCP (patient). A 45-year-old Adult female patient (non-pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 19Apr2021 at 08:00 AM (Lot number: Unknown) (at the age of 45-year-old) as DOSE 1, SINGLE for covid-19 immunisation.The patient was not pregnant at the time of vaccination. Medical history included Known allergies to Fragrances. The patient was not diagnosed with COVID-19, Prior to vaccination. Concomitant medications included Multivitamin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 20Apr2021, the patient experienced tiredness, low back stiffness, pain, severe shoulder pain, burning and cannot lift arm and painful armpit. No treatment was received to treat the events. The patient outcome of the events was not resolved at the time of this report.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Pain
Clinical narrative: Tiredness; Low back stiffness; pain; Severe shoulder pain; burning; cannot lift arm; Painful armpit; This is a spontaneous report from a contactable Consumer or other non-HCP (patient). A 45-year-old Adult female patient (non-pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 19Apr2021 at 08:00 AM (Lot number: Unknown) (at the age of 45-year-old) as DOSE 1, SINGLE for covid-19 immunisation.The patient was not pregnant at the time of vaccination. Medical history included Known allergies to Fragrances. The patient was not diagnosed with COVID-19, Prior to vaccination. Concomitant medications included Multivitamin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 20Apr2021, the patient experienced tiredness, low back stiffness, pain, severe shoulder pain, burning and cannot lift arm and painful armpit. No treatment was received to treat the events. The patient outcome of the events was not resolved at the time of this report.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Tinnitus
Clinical narrative: I developed tinnitus, a ringing in the ears after my first shot which I never had; It became even worse after the 2nd dose; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) on an unknown date as a single dose for COVID-19 immunisation. The patient did not have any medical history. Concomitant medications included dexmethylphenidate hydrochloride (FOCALIN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 20:00 after the first vaccination the patient experienced tinnitus, a ringing in the ears  which patient had never had. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) on 21Apr2021 (at the age of 26-year-old) as a single dose for COVID-19 immunisation. On an unknown date in Apr2021 (after the second vaccination)  Patient reported that the event tinnitus had worsened. The patient reported that the hearing was checked and there appeared to be no reduction in hearing, but the ringing was having an impact. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events tinnitus and tinnitus condition worsened were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pain in extremity, Somnolence
Clinical narrative: Arm soreness; Drowsiness; Overall muscle ache; This is a spontaneous report from a contactable consumer. A 28-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via intramuscular route of administration in the left arm on 23Apr2021 at 10:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamins (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via intramuscular route of administration in the left arm on 01Apr2021 at 11:30 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 19:00, the patient experienced arm soreness, drowsiness and overall muscle ache. Therapeutic measures were taken as a result of the events which included treatment with ibuprofen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm soreness, drowsiness and overall muscle ache was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Decreased appetite, Headache, Hyperacusis, Pain, Photophobia
Clinical narrative: Very high fever; Body ache; Headaches; Sensitive to light and noises; Sensitive to light and noises; Lack of appetite; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on an unknown date in 2021 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic cough. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 17:00, the patient experienced very high fever, body ache, headaches, sensitive to light and noises and lack of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Acetaminophen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very high fever, body ache, headaches, sensitive to light and noises and lack of appetite was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Very high fever; Body ache; Headaches; Sensitive to light and noises; Sensitive to light and noises; Lack of appetite; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0183) via an unspecified route of administration in the left arm on an unknown date in 2021 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic cough. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 17:00, the patient experienced very high fever, body ache, headaches, sensitive to light and noises and lack of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Acetaminophen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very high fever, body ache, headaches, sensitive to light and noises and lack of appetite was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Herpes zoster, Hypoaesthesia, Nausea
Clinical narrative: Shingles- 14 days after second vaccine; Dead arm; Back pain; Fever; Chills; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Apr2021 at 17:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 17:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 27Apr2021, the patient experienced dead arm, back pain, fever, chills and nausea. On 10May2021, 14 days after second vaccine, the patient experienced shingles. The adverse events resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The patient received valacyclovir hydrochloride (VALTREX) as treatment for the reported events. The clinical outcome of the events dead arm, back pain, fever, chills, nausea and shingles was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Shingles- 14 days after second vaccine; Dead arm; Back pain; Fever; Chills; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Apr2021 at 17:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 17:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 27Apr2021, the patient experienced dead arm, back pain, fever, chills and nausea. On 10May2021, 14 days after second vaccine, the patient experienced shingles. The adverse events resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The patient received valacyclovir hydrochloride (VALTREX) as treatment for the reported events. The clinical outcome of the events dead arm, back pain, fever, chills, nausea and shingles was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Joint pain started after first 24 hours across entire body.; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the left arm on 03May2021 at 16:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included sleep apnea. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 12Apr2021 at 15:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04May2021 after the first 24 hours (also reported at 15:30), the patient experienced joint pain across the entire body. It had since subsided everywhere, but constant, persistent pain continued in both the knees, whereas previously, there was no joint pain. The patient had no history of joint pain. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event joint pain across entire body and persistent pain continued in both the knees was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Diagnosed with shingles on the left side of my abdomen and back; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 26Apr2021 at 09:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 22:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. On 07May2021 at 06:00, the patient was diagnosed with shingles on the left side of abdomen and back. The event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event and included treatment with unspecified anti-viral medication. The clinical outcome of the event shingles was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Pain, Pyrexia
Clinical narrative: Full body aches; Nausea; Vomiting; Fever; Fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 14:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atomoxetine hydrochloride (STRATTERA) for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 11Apr2021 at 11:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 13May2021 at 03:00 the patient experienced full body aches, nausea, vomiting, fever, fatigue and headache. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events full body aches, nausea, vomiting, fever, fatigue and headache were resolving at the time of report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Full body aches; Nausea; Vomiting; Fever; Fatigue; Headache; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 14:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atomoxetine hydrochloride (STRATTERA) for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 11Apr2021 at 11:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 13May2021 at 03:00 the patient experienced full body aches, nausea, vomiting, fever, fatigue and headache. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events full body aches, nausea, vomiting, fever, fatigue and headache were resolving at the time of report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Tinnitus
Clinical narrative: ringing in the left ear; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK5730) via an unspecified route of administration in the left arm on 23Dec2020 at 14:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. The patient was allergic to intravenous pyelogram (IVP) dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cyanocobalamin (B-12), esomeprazole sodium (NEXUIM), losartan (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and rosuvastatin calcium (ROSUVAS); all taken from unknown dates for unknown indications and unknown if ongoing. On an unknown date in Jan2021, the patient experienced ringing in the left ear. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in 2021, the patient underwent hearing tests and the results were unknown. Therapeutic measures were taken as a result of the event and included treatment with hearing tests and changing of medications (unspecified). The clinical outcome of the event ringing in the left ear was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Muscle spasms, Myalgia, Tendon pain, Tendonitis
Clinical narrative: Soreness persisted in my left shoulder, and then spread to other large muscles/ Wrists and shoulders became so painful/ arthritic joint pain; Tight muscles made tendons sore.; The large muscle pain and cramps; The large muscle pain and cramps; Arthritic joint pain perhaps tendonitis.; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 16Apr2021 at 12:30 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and very mild arthritis. The patient had no known allergies to medications, food and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 22Mar2021 at 11:45 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within 4 weeks prior to the COVID vaccine. On 17Apr2021, the patient experienced soreness persisted in the left shoulder and then spread to other large muscles, tight muscles made tendons sore, wrists and shoulders became so painful that the patient had difficulty pulling covers up at night, and buttoning shirts, the large muscle pain and cramps were currently getting better, but still had what could best be described as arthritic joint pain and perhaps tendonitis. The patient had made an appointment to discuss these issues with his doctor. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcomes of the events soreness persisted in the left shoulder and then spread to other large muscles, tight muscles made tendons sore, wrists and shoulders became so painful that the patient had difficulty pulling covers up at night, and buttoning shirts, the large muscle pain and cramps were currently getting better, but still had what could best be described as arthritic joint pain and perhaps tendonitis were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pruritus, Vaccination site mass
Clinical narrative: bump still remains from shot; itchy; Every morning I feel as though I may vomit.; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: LDCPH) via an unspecified route of administration in the left arm on 20Apr2021 at 05:30 (at the age of 25-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included multivitamin (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: LDCPH) via an unspecified route of administration in the left arm on 31Mar2021 as a single dose for COVID-19 immunisation. On 21Apr2021 at 09:15, every morning, the patient felt as though he may vomit, bump still remains from shot and itchy a few times. Therapeutic measures were not taken as a result of the events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome for the events felt as though he may vomit, bump still remains from shot and itchy a few times were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Moderate injection site pain; Mild redness around injection site; Mild swelling around injection site; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the right arm on 12May2021 at 16:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit hyperactivity disorder (ADHD) and major depressive disorder (MDD). The patient had known allergies to lactose. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lisdexamfetamine mesilate (VYVANSE), lamotrigine (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and buspirone hydrochloride (BUSPIRON); all from unknown dates for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 22:00, the patient experienced moderate injection site pain, mild redness around injection site and mild swelling around injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate injection site pain, mild redness around injection site and mild swelling around injection site was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Pain in jaw, Paraesthesia, Pruritus, Vaccination site pain
Clinical narrative: Jaw pain; Lightheadedness; Itching/pins and needles sensation throughout right arm; Itching/pins and needles sensation throughout right arm; Soreness at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date, in 2021 the patient experienced light headedness for about 1 hour after vaccination, itching/pins and needles sensation throughout right arm for about 2 hours after vaccination, moderate jaw pain for 48 hours after vaccination and intense soreness at vaccination site starting 12 hours after vaccination which lasted for 48 hours after vaccination.  Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events light headedness was resolved on an unknown date, in 2021 (after duration of 1 hour), itching/pins and needles sensation throughout right arm was resolved on an unknown date, in 2021 (after duration of 2 hours), soreness at injection site was resolved on an unknown date, in 2021 (after duration of 36 hours) and jaw pain was resolved on an unknown date, in 2021 (after duration of 48 hours).  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Lymphadenopathy, Pyrexia
Clinical narrative: Swollen lymph nodes; Fever 101; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the right arm on 10May2021 at 09:15 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medication taken within two weeks of vaccination was not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 19Apr2021 at 08:45 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 12May2021 at 06:00, the patient experienced swollen lymph nodes and fever 101. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. On 12May2021, the patient recorded body temperature and the result was 101 (unit unspecified). The clinical outcome of the events swollen lymph nodes was not recovered and that of fever 101 was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Cough, Fatigue, Myalgia
Clinical narrative: Pyrexia (102*F); Shivering; Myalgia; Non productive cough; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 30Apr2021 at 19:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. Medical history included HSV-2 Infection (patient reported no lesions or symptoms at time of vaccine or afterward) and COVID-19. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 07Apr2021 at 12:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. On 01May2021 at 08:00,  within 12 hours, the patient experienced pyrexia 102*F, shivering, myalgia, non-productive cough and fatigue. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pyrexia 102*F, shivering, myalgia, non-productive cough and fatigue were recovered on 02May2021, all symptoms dissipated within 24 hours.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Pyrexia (102*F); Shivering; Myalgia; Non productive cough; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 30Apr2021 at 19:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. Medical history included HSV-2 Infection (patient reported no lesions or symptoms at time of vaccine or afterward) and COVID-19. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 07Apr2021 at 12:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. On 01May2021 at 08:00,  within 12 hours, the patient experienced pyrexia 102*F, shivering, myalgia, non-productive cough and fatigue. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pyrexia 102*F, shivering, myalgia, non-productive cough and fatigue were recovered on 02May2021, all symptoms dissipated within 24 hours.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Tingling in axillary region (bilaterally) and right forearm and back and right pectoral area; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 19Apr2021 at 10:45 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 27Mar2021 at 09:15 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08May2021, the patient experienced tingling in axillary region (bilaterally) and right forearm and back and right pectoral area. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event (reported "Haven't received anything yet. Doctor's appt in hr"). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tingling in axillary region (bilaterally) and right forearm and back and right pectoral area was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pain of skin, Pyrexia
Clinical narrative: Fever; Chills; Body aches; Skin pain; Headache; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 12May2021 at 09:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO164) via an unspecified route of administration in the left arm on 20Apr2021 at 07:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. On 13May2021 at 03:00, the patient experienced fever, chills, body aches, skin pain and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever, chills, body aches, skin pain and headache was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation delayed
Clinical narrative: My menstrual cycle was delayed for 10 days; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration on 13Apr2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. On 04May2021, the patient's menstrual cycle was delayed for 10 days. Therapeutic measures were not taken as a result of the reported event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event menstrual cycle was delayed for 10 days was resolved on an unknown date in May2021.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Malaise
Clinical narrative: Tiredness; Injection site pain; Headache; Muscle pain; Chills; Joint pain; Fever; Light nausea; Feeling unwell; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0170) via an unspecified route of administration in the right arm on 12May2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and diabetes. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included triamterene (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN) and nitrofurantoin (MANUFACTURER UNKNOWN); all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the right arm on 21Apr2021 at 11:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 13May2021 at 02:00, the patient experienced tiredness, injection site pain, headache, muscle pain, chills, joint pain, fever, light nausea, feeling unwell and arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, injection site pain, headache, muscle pain, chills, joint pain, fever, light nausea, feeling unwell and arm pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pain in extremity, Pyrexia, Vaccination site pain
Clinical narrative: Tiredness; Injection site pain; Headache; Muscle pain; Chills; Joint pain; Fever; Light nausea; Feeling unwell; Arm pain; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0170) via an unspecified route of administration in the right arm on 12May2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and diabetes. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included triamterene (MANUFACTURER UNKNOWN), metformin (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN) and nitrofurantoin (MANUFACTURER UNKNOWN); all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received sulfamethoxazole; trimethoprim (BACTRIM) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the right arm on 21Apr2021 at 11:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 13May2021 at 02:00, the patient experienced tiredness, injection site pain, headache, muscle pain, chills, joint pain, fever, light nausea, feeling unwell and arm pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, injection site pain, headache, muscle pain, chills, joint pain, fever, light nausea, feeling unwell and arm pain were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.